Pharma

Sustained vision gains and reduced macular thickness at Week 52; ~2/3 avoided retreatment after Week 16, most needing only one additional injection; safety profile consistent.

Oral helicase‑primase inhibitor pritelivir is the first novel‑mechanism FDA‑approved HSV therapy in ~30 years; Phase 3 showed 63% vs 34% healing by Day 28. US availability expected before end of 2026.

Vamikibart showed sustained vision gains and reduced macular thickness at 52 weeks in MEERKAT and SANDCAT; FDA has accepted the BLA with a decision due by July 2027.

Remigromig met non-inferiority for mean BCVA change versus monthly ranibizumab at one year in DME; higher rates of PDR-related adverse events and discontinuations were reported.

Live attenuated vaccine cuts clinical signs and viraemia from three weeks post‑vaccination and confers protection for one year; authorised under exceptional circumstances; side effects are uncommon.

Positive opinions for Bovilis Lumpyvax and Stemyca; Mirataz SPC updated for overdose effects; Vaxxitek MA extended one year; Vetmedin re‑examination concluded positive by majority.

Combination therapy produced broader psoriasis-related and metabolic biomarker changes vs Taltz alone as early as Week 12, with greater reductions in inflammatory and neutrophil markers.

Phase 3 data show sustained PASI90/PASI100 and IGA 0/1 responses to Week 112, durable itch improvement, and no new safety signals.

First patient dosed in a randomized Phase 2a trial of AIC468, an antisense oligonucleotide targeting BK virus in adult kidney transplant recipients.

Showcased quality, global dual‑sourcing and European capacity (Dundalk 54,000 L, Wuppertal 12–24,000 L) alongside platform speeds for complex biologics and 1,064 active projects.